Ftse Mib
34.249,77
0,91%
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
NASDAQ Composite
15.927,90
2,03%
Bitcoin
63.113,78
-0,98%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistenza
Home Investire Azioni U.S.A. NASDAQ Olema Pharmaceuticals Inc (OLMA) Olema Pharmaceuticals Inc (OLMA) Notizie

Olema Pharmaceuticals Inc

OLMA
9,48
-0,35 (-3,56%)
27 Apr 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
08/4/202422:30GLOBEOlema Oncology to Participate in Canaccord Genuity 2024..
02/4/202422:29GLOBEOlema Oncology Reports Inducement Grants Under Nasdaq..
11/3/202421:31EDGAR2Form S-8 - Securities to be offered to employees in employee..
11/3/202421:15EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
11/3/202421:05EDGAR2Form 8-K - Current report
11/3/202421:03GLOBEOlema Oncology Reports Fourth Quarter and Full-Year 2023..
06/3/202413:03GLOBEOlema Oncology Announces Publication of Data Highlighting..
04/3/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202422:30GLOBEOlema Oncology Reports Inducement Grants Under Nasdaq..
29/2/202420:26EDGAR2Form 144 - Report of proposed sale of securities
14/2/202422:08EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202418:53EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202423:16EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
12/2/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
06/2/202413:01GLOBEOlema Oncology to Participate in Upcoming Investor..
05/2/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:30GLOBEOlema Oncology Reports Inducement Grants Under Nasdaq..
01/2/202421:24EDGAR2Form 144 - Report of proposed sale of securities
31/1/202422:21EDGAR2Form S-3 - Registration statement under Securities Act of..
31/1/202420:58EDGAR2Form 144 - Report of proposed sale of securities
29/1/202413:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202415:07EDGAR2Form 8-K - Current report
08/1/202414:18EDGAR2Form 8-K - Current report
08/1/202414:12GLOBEOlema Oncology Nominates OP-3136, an Orally Bioavailable..
05/1/202423:26EDGAR2Form 8-K - Current report
05/1/202423:25EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
02/1/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202422:01GLOBEOlema Oncology to Present at 42nd Annual J.P. Morgan..
29/12/202321:54EDGAR2Form 144 - Report of proposed sale of securities
19/12/202300:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202323:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202322:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202302:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202302:30EDGAR2Form 3/A - Initial statement of beneficial ownership of..
06/12/202313:48EDGAR2Form 8-K - Current report
05/12/202323:15EDGAR2Form 8-K - Current report
05/12/202318:27GLOBEOlema Oncology Announces Palazestrant Demonstrates..
04/12/202322:29GLOBEOlema Oncology Reports Inducement Grants Under Nasdaq..
01/12/202323:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/11/202316:20EDGAR2Form 144 - Report of proposed sale of securities
28/11/202323:10GLOBEOlema Oncology to Present New Palazestrant Clinical Data in..
23/11/202301:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/11/202301:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/11/202301:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/11/202301:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/11/202321:25EDGAR2Form 144 - Report of proposed sale of securities
22/11/202321:04EDGAR2Form 144 - Report of proposed sale of securities
Apertura: 9,87 Min: 9,51 Max: 10,09
Chiusura: 9,83

La tua Cronologia

NASDAQ
OLMA
Olema Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network